SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Alimera Sciences Announces Enrollment Of First Patient In Landmark NEW DAY Clinical Trial To Evaluate ILUVIEN As Baseline Therapy For Diabetic Macular Edema

ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic

 · 

ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces that it has enrolled the first patient in the company's NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg as a baseline therapy in patients diagnosed with diabetic macular edema (DME).
 

"The first patient enrolled in our NEW DAY trial is an important milestone initiating the opportunity to generate data that we believe has the potential to change the paradigm of DME treatment by offering patients a first-line treatment option that can maintain vision longer with fewer injections," said Rick Eiswirth, Alimera's President and Chief Executive Officer. "We have great confidence in this study as our FAME Study data supported the approval of ILUVIEN as first-line therapy in the U.S., and our real-world data from both the U.S. and Europe indicate that the benefits of ILUVIEN are maximized when used early in DME."